Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth buys Thiakis for $150 million

This article was originally published in Scrip

Executive Summary

Wyeth has bought Thiakis, a privately-held UK biotechnology company focused on obesity, for $150 million to boost its portfolio of metabolic disorder treatments. Imperial Innovations, a UK technology commercialisation and investment company that had a 23.7% stake in Thiakis, may receive a net cash payment of £22.2 million from the sale, and has rights to royalties on sales. Thiakis is developing TKS1225, an analogue of the peptide hormone oxyntomodulin, for obesity, including conditions associated with excess weight, such as type 2 diabetes and cardiovascular disease. Imperial retains the rights to royalties on sales of Thiakis products. Thiakis was founded in 2004 and raised £10 million from a syndicate of investors in 2006.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts